JP2024533153A - 投薬レジーム - Google Patents

投薬レジーム Download PDF

Info

Publication number
JP2024533153A
JP2024533153A JP2024513893A JP2024513893A JP2024533153A JP 2024533153 A JP2024533153 A JP 2024533153A JP 2024513893 A JP2024513893 A JP 2024513893A JP 2024513893 A JP2024513893 A JP 2024513893A JP 2024533153 A JP2024533153 A JP 2024533153A
Authority
JP
Japan
Prior art keywords
peg3
carboxy
aib
isoglu
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533153A5 (enExample
Inventor
ミゲル アスジャール エーヤスナプ
Original Assignee
ジーランド ファーマ エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド ファーマ エー／エス filed Critical ジーランド ファーマ エー／エス
Publication of JP2024533153A publication Critical patent/JP2024533153A/ja
Publication of JP2024533153A5 publication Critical patent/JP2024533153A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024513893A 2021-09-03 2022-09-02 投薬レジーム Pending JP2024533153A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21194879.9 2021-09-03
EP21194879 2021-09-03
EP22160234 2022-03-04
EP22160234.5 2022-03-04
PCT/EP2022/074420 WO2023031380A1 (en) 2021-09-03 2022-09-02 Dosage regime

Publications (2)

Publication Number Publication Date
JP2024533153A true JP2024533153A (ja) 2024-09-12
JP2024533153A5 JP2024533153A5 (enExample) 2024-10-09

Family

ID=84272918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513893A Pending JP2024533153A (ja) 2021-09-03 2022-09-02 投薬レジーム

Country Status (11)

Country Link
US (1) US20250073311A1 (enExample)
EP (1) EP4392054A1 (enExample)
JP (1) JP2024533153A (enExample)
KR (1) KR20240058121A (enExample)
AU (1) AU2022339044A1 (enExample)
CA (1) CA3228429A1 (enExample)
CL (1) CL2024000647A1 (enExample)
IL (1) IL311166A (enExample)
MX (1) MX2024002600A (enExample)
TW (1) TW202315882A (enExample)
WO (1) WO2023031380A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2026052859A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide
WO2026052861A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525890A (ja) * 2016-12-09 2019-09-12 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
JP2020500890A (ja) * 2016-12-09 2020-01-16 ジーランド・ファーマ・ア／エス Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
US20230129788A1 (en) * 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
IL301892A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
MX2023006280A (es) * 2020-12-16 2023-06-13 Zealand Pharma As Composicion farmaceutica de agonistas duales de glp-1/glp-2.
CA3200526A1 (en) * 2020-12-16 2022-06-23 Jesper Skodborg VILLADSEN Pharmaceutical composition of glp-1/glp-2 dual agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525890A (ja) * 2016-12-09 2019-09-12 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
JP2020500890A (ja) * 2016-12-09 2020-01-16 ジーランド・ファーマ・ア／エス Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Also Published As

Publication number Publication date
CL2024000647A1 (es) 2024-09-13
CA3228429A1 (en) 2023-03-09
WO2023031380A9 (en) 2024-02-22
WO2023031380A1 (en) 2023-03-09
KR20240058121A (ko) 2024-05-03
US20250073311A1 (en) 2025-03-06
MX2024002600A (es) 2024-03-22
EP4392054A1 (en) 2024-07-03
TW202315882A (zh) 2023-04-16
AU2022339044A1 (en) 2024-03-14
IL311166A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
US11395847B2 (en) Acylated GLP-1/GLP-2 dual agonists
EP3551652B1 (en) Glp-1/glp-2 dual agonists
JP2024533153A (ja) 投薬レジーム
WO2018104558A1 (en) Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) Acylated glp-1/glp-2 dual agonists
CN117979986A (zh) 给药方案
HK40111792A (en) Acylated glp-1/glp-2 dual agonists
CA3043151C (en) Acylated glp-1/glp-2 dual agonists
HK40007709A (en) Acylated glp-1/glp-2 dual agonists
HK40007709B (en) Acylated glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260406